ClinicalTrials.gg
Not yet recruitingNCT07941843LF-FOLFOXUpdated Nov 17, 2026

Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer

A Phase 2 interventional study of Lactoferrin and FOLFOX chemotherapy regimen in Colorectal Cancer and Chemotherapy-Induced Peripheral Neuropathy, sponsored by Damanhour University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Damanhour University · Phase 2, Interventional, and Supportive care

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled clinical trial aims to investigate the potential protective effects of oral lactoferrin supplementation against chemotherapy-related toxicities in patients with colorectal cancer receiving the FOLFOX regimen.

A total of 44 eligible adult patients will be randomly allocated into two parallel groups (22 patients per group). The control group will receive standard FOLFOX chemotherapy, while the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin (Pravotin) at a dose of 100 mg twice daily, starting from the first chemotherapy cycle and continuing throughout the planned chemotherapy course.

The study will evaluate peripheral neuropathy, gastrointestinal and hematological toxicities, oxidative stress and neuroprotective biomarkers.

Read the detailed description

Colorectal cancer is commonly treated with oxaliplatin-based chemotherapy regimens such as FOLFOX, which combines oxaliplatin, 5-fluorouracil, and leucovorin. Despite its therapeutic effectiveness, FOLFOX is associated with peripheral neuropathy, gastrointestinal toxicity, hematological abnormalities, and impaired quality of life.

Lactoferrin is an iron-binding glycoprotein with antioxidant, anti-inflammatory, immunomodulatory, and potential neuroprotective properties. These biological activities may help mitigate chemotherapy-induced toxicities.

This study will investigate the potential protective effects of lactoferrin supplementation in 44 patients with histologically confirmed colorectal cancer who are scheduled to receive at least six cycles of FOLFOX chemotherapy at Damanhour Oncology Center.

Eligible participants will be randomly assigned in a 1:1 ratio to receive either standard FOLFOX chemotherapy alone or standard FOLFOX chemotherapy combined with oral lactoferrin 100 mg twice daily.

Participants will undergo clinical evaluations, laboratory monitoring, and assessment of chemotherapy-related adverse events. Laboratory investigations will include complete blood count, kidney and liver function tests, and serum biomarkers including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and malondialdehyde (MDA).

Clinical assessments and laboratory investigations will be conducted during chemotherapy, with final assessments at the completion of the planned chemotherapy course.

02

Conditions studied

  • Colorectal Cancer
  • Chemotherapy-Induced Peripheral Neuropathy

Keywords

  • Oxidative Stress
  • Chemotherapy-Induced Toxicity
  • Oxaliplatin
  • FOLFOX
  • Lactoferrin
03

In context

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's planned enrollment of 50 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Damanhour University is the lead sponsor of 79 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 years or older with confirmed colorectal cancer.
  • Patients scheduled to receive at least six cycles of FOLFOX chemotherapy.
  • (ECOG) performance status of 0-2.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing peripheral neuropathy of grade 1 or higher.
  • Hereditary neuromuscular disorders.
  • Advanced liver disease, defined as liver enzymes greater than three times the or established cirrhosis.
  • Chronic kidney disease with an estimated (eGFR) below 60 mL/min/1.73 m².
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Standard FOLFOX Chemotherapy

    Participants assigned to the control group will receive standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin according to the routine oncology treatment protocol.

    Drug: FOLFOX chemotherapy regimen

  • Experimental
    FOLFOX Plus Lactoferrin

    Participants assigned to the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin supplementation (Pravotin) at a dose of 100 mg twice daily, initiated at the first chemotherapy cycle and continued throughout the planned chemotherapy course.

    Dietary Supplement: Lactoferrin · Drug: FOLFOX chemotherapy regimen

Interventions

  • Dietary supplementLactoferrin

    Oral lactoferrin supplementation (Lactomash), administered at a dose of 100 mg twice daily (total daily dose: 200 mg), starting from the first FOLFOX chemotherapy cycle and continuing throughout the planned chemotherapy course.

  • DrugFOLFOX chemotherapy regimen

    Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol.

06

What researchers measure

Primary outcomes

  1. Incidence of Oxaliplatin-Induced Peripheral Neuropathy

    Proportion of participants developing peripheral neuropathy during FOLFOX chemotherapy, assessed and graded according to biomarkers.

    Time frame: From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • - Macciò A, et al. The Oncologist. 2010
  • Lesser GJ, Irby MB, Taylor RC, Snavely A, Case D, Wang A, Dietrich A, Duncan S. Lactoferrin supplementation for taste and smell abnormalities among patients receiving cancer chemotherapy. Support Care Cancer. 2022 Mar;30(3):2017-2025. doi: 10.1007/s00520-021-06609-8. Epub 2021 Oct 13. PubMed 34642792 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

Of 498 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 75. This study's planned 3 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941843
Lead sponsor
Damanhour University
Responsible party
Noha El Bassiouny (Assistant professor of clinical pharmacy and pharmacy practice, Damanhour University) — Principal investigator
First posted
Nov 17, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Toka M El-Banna, Clinical pharmacy TA
Contact
tokaelbanna@gmail.com
00201018546392

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion